

Bohdan Nosyk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8384380/bohdan-nosyk-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

2,769
citations

29
h-index

46
g-index

147
ext. papers

3,360
ext. citations

4.9
avg, IF

4.93
L-index

#	Paper	IF	Citations
137	Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada.. <i>Drug and Alcohol Dependence</i> , 2022 , 233, 109375	4.9	0
136	MHepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID.. <i>Trials</i> , 2022 , 23, 341	2.8	0
135	Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform.. <i>Journal of Substance Abuse Treatment</i> , 2022 , 108784	4.2	
134	Opioid use disorder Cascade of care framework design: A roadmap. <i>Substance Abuse</i> , 2022 , 43, 1207-1214	4.8	0
133	High prevalence of unmet healthcare need among people who use illicit drugs in a Canadian setting with publicly-funded interdisciplinary primary care clinics. <i>Substance Abuse</i> , 2021 , 42, 760-766	3.8	0
132	Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. <i>Journal of Substance Abuse Treatment</i> , 2021 , 108647	4.2	0
131	The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment. <i>Health Economics (United Kingdom)</i> , 2021 , 30, 1222-1238	2.4	0
130	Opioid analgesic prescribing for opioid-naïve individuals prior to identification of opioid use disorder in British Columbia, Canada. <i>Addiction</i> , 2021 , 116, 3422-3432	4.6	1
129	Diagnosis of Opioid Use Disorder by Youths Assessed in Acute Care Settings in British Columbia, Canada. <i>Journal of Pediatrics</i> , 2021 , 232, 243-250	3.6	
128	Non-inferior antibody levels for HPV16/18 after extended two-dose schedules compared with a six-month interval: findings of a systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 3554-3561	4.4	1
127	Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV: an analysis in six US cities. <i>Aids</i> , 2021 , 35, 2169-2179	3.5	
126	Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. <i>BMJ Open</i> , 2021 , 11, e048353	3	4
125	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021 , 88, 102726	5.5	2
124	The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2021 , 72, e828-e834	11.6	7
123	Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 729-737	5.1	4
122	Cohort profile: The provincial substance use disorder cohort in British Columbia, Canada. <i>International Journal of Epidemiology</i> , 2021 , 49, 1776	7.8	1
121	Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider Application. <i>Current HIV/AIDS Reports</i> , 2021 , 18, 176-185	5.9	2

120	Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018. <i>Drug and Alcohol Dependence</i> , 2021 , 225, 108799	4.9	1
119	Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. <i>Lancet HIV,the</i> , 2021 , 8, e581-e590	7.8	0
118	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 979-993	14.5	50
117	Opioid Use Disorder and Perinatal Outcomes. <i>Pediatrics</i> , 2021 , 148,	7.4	3
116	The cascade of care for opioid use disorder among youth in British Columbia, 2018. <i>Journal of Substance Abuse Treatment</i> , 2021 , 130, 108404	4.2	4
115	The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14.. <i>Journal of Substance Abuse Treatment</i> , 2021 , 108714	4.2	1
114	Ending the HIV epidemic in the USA: an economic modelling study in six cities. <i>Lancet HIV,the</i> , 2020 , 7, e491-e503	7.8	27
113	Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. <i>Medical Decision Making</i> , 2020 , 40, 3-16	2.5	16
112	Contact Tracing for COVID-19: An Opportunity to Reduce Health Disparities and End the Human Immunodeficiency Virus/AIDS Epidemic in the United States. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2259-2269	11.6	8
111	Can the "Ending the HIV Epidemic" initiative transition the USA towards HIV/AIDS epidemic control?. <i>Aids</i> , 2020 , 34, 2325-2328	3.5	3
110	"Ending the Epidemic" Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2968-2971	11.6	18
109	Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia. <i>Drug and Alcohol Dependence</i> , 2020 , 207, 107798	4.9	3
108	The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. <i>Addiction</i> , 2020 , 115, 1482-1493	4.6	26
107	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020 , 34, 447-458	3.5	19
106	Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. <i>Drug and Alcohol Dependence</i> , 2020 , 217, 108337	4.9	1
105	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. <i>Value in Health</i> , 2020 , 23, 1534-1542	3.3	3
104	Non-disclosure of drug use in outpatient health care settings: Findings from a prospective cohort study in Vancouver, Canada. <i>International Journal of Drug Policy</i> , 2020 , 84, 102873	5.5	0
103	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020 , 10, e036102	3	8

102	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020 , 222, S301-S311	7	0
101	Commentary on Krawczyk et al. (2020): Reinforcing the case for evidence-based treatment of opioid use disorder. <i>Addiction</i> , 2020 , 115, 1695-1696	4.6	
100	Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. <i>BMJ, The</i> , 2020 , 368, m772	5.9	45
99	Geographic variation in the costs of medical care for people living with HIV in British Columbia, Canada. <i>BMC Health Services Research</i> , 2019 , 19, 626	2.9	
98	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019 , 37, 1219-1239	4.4	3
97	Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. <i>PLoS ONE</i> , 2019 , 14, e0217559	3.7	20
96	Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019 , 18, 2325958218821962	1.7	3
95	Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. <i>Lancet HIV,the</i> , 2019 , 6, e531-e539	7.8	11
94	Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2019 , 69, 2195-2198	11.6	14
93	Identifying mental health and substance use disorders using emergency department and hospital records: a population-based retrospective cohort study of diagnostic concordance and disease attribution. <i>BMJ Open</i> , 2019 , 9, e030530	3	6
92	Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States. <i>Aids</i> , 2019 , 33, 1491-1500	3.5	3
91	The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013. <i>Clinical Infectious Diseases</i> , 2018 , 66, 765-777	11.6	13
90	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> , 2018 , 8, e019115	3	12
89	Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS. <i>AIDS and Behavior</i> , 2018 , 22, 234-244	4.3	2
88	Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. <i>Annals of Internal Medicine</i> , 2018 , 168, 10-19	8	29
87	Impact of Patient-Provider Attachment on Hospital Readmissions Among People Living With HIV: A Population-Based Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 551-558	3.1	3
86	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. <i>Lancet Public Health, The</i> , 2018 , 3, e429-e437	22.4	23
85	Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. <i>AIDS and Behavior</i> , 2018 , 22, 3071-3082	4.3	23

84	Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver's Downtown Eastside. <i>International Journal of Drug Policy</i> , 2018 , 59, 16-23	5.5	10
83	Joint Utility Estimators in Substance Use Disorders. <i>Value in Health</i> , 2017 , 20, 458-465	3.3	10
82	The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. <i>Addiction</i> , 2017 , 112, 838-851	4.6	26
81	Quality of life as an outcome of opioid use disorder treatment: A systematic review. <i>Journal of Substance Abuse Treatment</i> , 2017 , 76, 88-93	4.2	33
80	Estimating State Transitions for Opioid Use Disorders. <i>Medical Decision Making</i> , 2017 , 37, 483-497	2.5	10
79	Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?. <i>International Journal of Drug Policy</i> , 2017 , 47, 169-176	5.5	4
78	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study. <i>Lancet HIV</i> , 2017 , 4, e303-e310	7.8	24
77	A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21941	5.4	17
76	The costs of crime associated with stimulant use in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2017 , 180, 304-310	4.9	7
75	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. <i>International Journal of Drug Policy</i> , 2017 , 49, 32-40	5.5	51
74	Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1496-1503	11.6	8
73	Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2017 , 20, e25011	5.4	17
72	Increased drug use and the timing of social assistance receipt among people who use illicit drugs. <i>Social Science and Medicine</i> , 2016 , 171, 94-102	5.1	14
71	Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2016 , 168, 22-29	4.9	23
70	Protocol of the impact of alternative social assistance disbursement on drug-related harm (TASA) study: a randomized controlled trial to evaluate changes to payment timing and frequency among people who use illicit drugs. <i>BMC Public Health</i> , 2016 , 16, 668	4.1	4
69	Cost-Effectiveness of the One4All HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China. <i>PLoS ONE</i> , 2016 , 11, e0167308	3.7	16
68	Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. <i>Addiction</i> , 2016 , 111, 675-84	4.6	19
67	Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. <i>HIV Medicine</i> , 2016 , 17, 269-79	2.7	7

66	Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder. <i>Journal of Substance Abuse Treatment</i> , 2016 , 67, 30-7	4.2	8
65	Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. <i>Pharmacoeconomics</i> , 2015 , 33, 243-53	4.4	14
64	The need for standardisation of the HIV continuum of care. <i>Lancet HIV,the</i> , 2015 , 2, e225-6	7.8	13
63	Gender differences in mortality among treated opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2015 , 155, 228-35	4.9	34
62	Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. <i>Lancet HIV,the</i> , 2015 , 2, e393-400	7.8	29
61	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1157-65	11.6	39
60	The Expanded HIV care in opioid substitution treatment (EHOST) cluster-randomized, stepped-wedge trial: A study protocol. <i>Contemporary Clinical Trials</i> , 2015 , 45, 201-209	2.3	5
59	The rise of marijuana and the fall of cocaine in the United States: for better, for worse?. <i>Addiction</i> , 2015 , 110, 737-8	4.6	2
58	Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. <i>Addiction</i> , 2015 , 110, 996-1005	4.6	77
57	The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence. <i>Drug and Alcohol Dependence</i> , 2015 , 146, e53-e54	4.9	4
56	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. <i>International Journal of Epidemiology</i> , 2015 , 44, 58-67	7.8	27
55	Characterizing retention in HAART as a recurrent event process: insights into cascade churn. <i>Aids</i> , 2015 , 29, 1681-9	3.5	30
54	The causal effect of opioid substitution treatment on HAART medication refill adherence. <i>Aids</i> , 2015 , 29, 965-73	3.5	31
53	Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?. <i>PLoS ONE</i> , 2015 , 10, e0143836	3.7	32
52	Short term health-related quality of life improvement during opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2015 , 157, 121-8	4.9	24
51	Dynamics in the costs of criminality among opioid dependent individuals. <i>Drug and Alcohol Dependence</i> , 2014 , 144, 193-200	4.9	19
50	Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. <i>Drug and Alcohol Dependence</i> , 2014 , 143, 149-57	4.9	24
49	Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure. <i>Medical Decision Making</i> , 2014 , 34, 800-8	3.5	10

48	Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. <i>Drug and Alcohol Dependence</i> , 2014 , 140, 69-77	4.9	19
47	High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. <i>PLoS ONE</i> , 2014 , 9, e115277	3.7	54
46	Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?. <i>Current HIV/AIDS Reports</i> , 2014 , 11, 468-78	5.9	18
45	Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). <i>International Journal of Epidemiology</i> , 2014 , 43, 1073-81	7.8	46
44	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2014 , 23, 257-64	3.7	21
43	Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011. <i>Medical Care</i> , 2014 , 52, 362-9	3.1	4
42	Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, e94-e109	3.1	15
41	The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2014 , 14, 40-49	25.5	151
40	Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. <i>PLoS ONE</i> , 2014 , 9, e87872	3.7	226
39	Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006. <i>Substance Use and Misuse</i> , 2013 , 48, 671-82	2.2	5
38	Increasing availability of illicit drugs among people who inject drugs in Bangkok, Thailand. <i>Drug and Alcohol Dependence</i> , 2013 , 132, 251-6	4.9	4
37	Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. <i>Aids</i> , 2013 , 27, 1159-65	3.5	19
36	The temporal relationship between drug supply indicators: an audit of international government surveillance systems. <i>BMJ Open</i> , 2013 , 3, e003077	3	29
35	A call for evidence-based medical treatment of opioid dependence in the United States and Canada. <i>Health Affairs</i> , 2013 , 32, 1462-9	7	98
34	Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study. <i>American Journal of Epidemiology</i> , 2013 , 177, 675-82	3.8	33
33	Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions. <i>HIV Medicine</i> , 2013 , 14, 581-2	2.7	11
32	Offender diversion into substance use disorder treatment: the economic impact of California's proposition 36. <i>American Journal of Public Health</i> , 2013 , 103, 1096-102	5.1	20
31	Response to Lancaster et al. Generalizability and scalability of HIV treatment as prevention. <i>Aids</i> , 2013 , 27, 2319-20	3.5	

30	Client demands for unsafe sex: the socioeconomic risk environment for HIV among street and off-street sex workers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 522-31	3.1	58
29	HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 653-9	3.1	24
28	Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. <i>PLoS ONE</i> , 2013 , 8, e54416	3.7	35
27	Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. <i>Addiction</i> , 2012 , 107, 1621-9	4.6	45
26	Increases in the availability of prescribed opioids in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2012 , 126, 7-12	4.9	20
25	Estimating the economic value of British Columbia's domestic cannabis market: implications for provincial cannabis policy. <i>International Journal of Drug Policy</i> , 2012 , 23, 436-41	5.5	12
24	Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. <i>Cmaj</i> , 2012 , 184, E317-28	3.5	60
23	Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. <i>Aids</i> , 2012 , 26, 1491-500	3.5	11
22	The evolving landscape of the economics of HIV treatment and prevention. <i>PLoS Medicine</i> , 2012 , 9, e1001174	1.7	7
21	Disparities in the burden of HIV/AIDS in Canada. <i>PLoS ONE</i> , 2012 , 7, e47260	3.7	30
20	Development and validation of a composite programmatic assessment tool for HIV therapy. <i>PLoS ONE</i> , 2012 , 7, e47859	3.7	17
19	Health related quality of life trajectories of patients in opioid substitution treatment. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 259-64	4.9	45
18	The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. <i>PLoS ONE</i> , 2011 , 6, e27059	3.7	14
17	Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment. <i>Canadian Journal of Public Health</i> , 2010 , 101, 210-2	3.2	11
16	Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. <i>Journal of Substance Abuse Treatment</i> , 2010 , 38, 408-11	4.2	22
15	Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. <i>Journal of Substance Abuse Treatment</i> , 2010 , 39, 22-31	4.2	79
14	The quality of eight health status measures were compared for chronic opioid dependence. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1132-44	5.7	27
13	Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. <i>Drug and Alcohol Dependence</i> , 2010 , 111, 50-7	4.9	20

12	The effect of motivational status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study. <i>Drug and Alcohol Dependence</i> , 2010 , 111, 161-5	4.9	35
11	Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. <i>Clinical Trials</i> , 2009 , 6, 261-71	2.2	34
10	Proportional hazards frailty models for recurrent methadone maintenance treatment. <i>American Journal of Epidemiology</i> , 2009 , 170, 783-92	3.8	68
9	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. <i>Quality of Life Research</i> , 2009 , 18, 815-24	3.7	9
8	Value of information of a clinical prediction rule: informing the efficient use of healthcare and health research resources. <i>International Journal of Technology Assessment in Health Care</i> , 2008 , 24, 112-9 ^{1.8}	1.8	8
7	The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. <i>Journal of Urban Health</i> , 2008 , 85, 812-25	5.8	39
6	Impact of the recall period on measuring health utilities for acute events. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 1413-9	2.4	11
5	The cost-effectiveness of three strategies for the surgical treatment of symptomatic primary hyperparathyroidism. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2653-60	3.1	13
4	Safety and clinical effectiveness of midazolam versus propofol for procedural sedation in the emergency department: a systematic review. <i>Academic Emergency Medicine</i> , 2008 , 15, 1-8	3.4	43
3	A cost-effectiveness analysis of propofol versus midazolam for procedural sedation in the emergency department. <i>Academic Emergency Medicine</i> , 2008 , 15, 32-9	3.4	17
2	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1729-36	4.1	20
1	The effect of homelessness on hospitalisation among patients with HIV/AIDS. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007 , 19, 546-53	2.2	10